Fibroblasts induce heparin synthesis in chondroitin sulfate E containing human bone marrow-derived mast cells.
Human bone marrow-derived mast cells (hBMMCs), differentiated in vitro in suspension culture and under the influence of human peripheral blood mononuclear cells conditioned medium (hCM), were tested for their response to recombinant human interleukin-3 (rhIL-3) and for their behavior in different microenvironments. The hBMMCs were incubated in the presence of rhIL-3 and the changes in their proliferation rate were determined. Recombinant hIL-3 induced a more than sixfold increase in 3H-thymidine uptake into the hBMMC DNA in a dose-dependent manner. Human CM used as a control for proliferation response induced a more than eightfold maximal proliferation rate increase. Rabbit anti-rhIL-3 completely inhibited hBMMC 3H-thymidine uptake induced by rhIL-3 and decreased the hCM-induced proliferation by approximately 50%. These hBMMCs were cocultured with four different mytomicin C-treated cell monolayers and assayed for phenotypic changes. After only 2 days in coculture with either embryonic mouse skin-derived fibroblasts (MESFs) or human skin-derived fibroblasts (HSFs), a marked increase in granule number and density was noted on staining with toluidine blue. Mast cells that initially stained alcian blue+/safranin- at day 0 of coculture became alcian blue+/safranin+ during the coculture period. Human BMMC proteoglycan synthesis shifted from approximately 85% chondroitin sulfate E to approximately 60% heparin within 14 to 19 days of coculture with the MESF monolayer and to approximately 50% heparin within 19 days of coculture with the HSF monolayer. None of the above-mentioned changes were noted in cocultures of hBMMCs with 3T3 cell line fibroblast monolayers or in cocultures with bovine vascular endothelium (BVE) cell monolayers. These results demonstrate microenvironmental effects exerted by the MESF and HSF monolayers on IL-3-dependent hBMMCs similar to those reported in the conversion of murine mast cell phenotype.
Gilead
L
L
Institute of Biochemistry, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Bibi
O
O
Razin
E
E
D000423:Alcian Blue; D000818:Animals; D000970:Antineoplastic Agents; D001854:Bone Marrow Cells; D002478:Cells, Cultured; D002807:Chondroitin / Q000031:analogs & derivatives*; D002809:Chondroitin Sulfates / Q000032:analysis*; D005347:Fibroblasts / Q000502:physiology*; D006493:Heparin / Q000096:biosynthesis*; D006651:Histocytochemistry / Q000379:methods; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology; D008407:Mast Cells / Q000032:analysis / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D010619:Phenazines; D010641:Phenotype; D011509:Proteoglycans / Q000096:biosynthesis; D011994:Recombinant Proteins / Q000494:pharmacology; D012867:Skin / Q000166:cytology; D013936:Thymidine / Q000378:metabolism; D014316:Tritium
D000970:Antineoplastic Agents; D007377:Interleukin-3; D010619:Phenazines; D011509:Proteoglycans; D011994:Recombinant Proteins; D014316:Tritium; D006493:Heparin; D002807:Chondroitin; D002809:Chondroitin Sulfates; D000423:Alcian Blue; D013936:Thymidine; C009195:safranine T